Loading mutual fund details…
Nippon India Nifty Pharma ETF is an etf scheme managed by Nippon India Mutual Fund. Three-year compounded annual return is 23.93%, placing it in the 82nd percentile of ETF peers. It has ranked in the top half of its category for 2 of the last 4 reported years. The total expense ratio is 0.21% on assets of ₹1,356Cr. The fund is currently managed by Jitendra Tolani, appointed within the last year.
Lower is better.
| Holding | Sector | Weight |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
ETF-specific data. Tracking error is the standard-deviation of (ETF return − index return) over the trailing year.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Sun Pharmaceutical Industries Limited | Healthcare | 22.53% |
| Divi's Laboratories Limited | Healthcare | 9.73% |
| Dr. Reddy's Laboratories Limited | Healthcare | 9.49% |
| Cipla Limited | Healthcare | 8.67% |
| Lupin Limited | Healthcare | 6.58% |
| Torrent Pharmaceuticals Limited | Healthcare | 5.15% |
| Laurus Labs Limited | Healthcare | 5.04% |
| Aurobindo Pharma Limited | Healthcare | 4.57% |
| Glenmark Pharmaceuticals Limited | Healthcare | 4.27% |
| Alkem Laboratories Limited | Healthcare | 3.71% |
| Biocon Limited | Healthcare | 3.02% |
| Mankind Pharma Limited | Healthcare | 2.99% |
| Zydus Lifesciences Limited | Healthcare | 2.63% |
| IPCA Laboratories Limited | Healthcare | 2.50% |
| JB Chemicals & Pharmaceuticals Limited | Healthcare | 1.97% |
| Gland Pharma Limited | Healthcare | 1.64% |
| Abbott India Limited | Healthcare | 1.55% |
| Ajanta Pharma Limited | Healthcare | 1.40% |
| Wockhardt Limited | Healthcare | 1.36% |
| Piramal Pharma Limited | Healthcare | 1.18% |
| Sector | Holdings | Weight |
|---|---|---|
| Pharmaceuticals & Biotechnology | 20 | 99.98% |
Active bets vs the average ETF fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
How crowded into the same stocks is this fund vs the largest fund in its category?
Category leader = highest-AUM scheme in the same SEBI category. A high overlap-of-weight number means the fund is concentrated into the same names as the leader (crowded); a low one means it's genuinely differentiated.
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Top-10 weight 79.7% means the manager bets the fund's outcome on a small basket. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: ETF.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.